BioGaia AB/Skr BIOG B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioGaia AB
BioGaia AB is a Swedish biotechnology company that specializes in the development and commercialization of probiotic products. The company's core business revolves around creating proprietary probiotic strains that are used to support digestive health. Notably, BioGaia's products are often formulated into dietary supplements, as well as being incorporated into infant formula and dairy products. Founded in 1990, BioGaia is headquartered in Stockholm, Sweden, and operates on a global scale, distributing its products in over 100 countries. The company is strategically positioned through its research collaborations and partnerships, enhancing its competitive strengths in the probiotic segment.
- Ticker
- Skr BIOG B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 251
- Headquarters
- Stockholm, Sweden
- Website
- www.biogaiagroup.com
BioGaia AB Metrics
BasicAdvanced
kr 12B
31.12
kr 3.87
0.27
kr 4.00
1.36%
Price and volume
Market cap
kr 12B
Beta
0.27
52-week high
kr 136.30
52-week low
kr 96.20
Average daily volume
199K
Dividend rate
kr 4.00
Financial strength
Current ratio
5.141
Quick ratio
2.57
Interest coverage (TTM)
314.02%
Profitability
EBITDA (TTM)
483.817
Gross margin (TTM)
72.74%
Net profit margin (TTM)
23.67%
Operating margin (TTM)
28.22%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
kr 6,590,000
Management effectiveness
Return on assets (TTM)
19.86%
Return on equity (TTM)
32.10%
Valuation
Price to earnings (TTM)
31.116
Price to revenue (TTM)
7.362
Price to book
9.97
Price to tangible book (TTM)
11.47
Price to free cash flow (TTM)
47.14
Free cash flow yield (TTM)
2.12%
Free cash flow per share (TTM)
2.554
Dividend yield (TTM)
3.32%
Forward dividend yield
1.36%
Growth
Revenue change (TTM)
13.13%
Earnings per share change (TTM)
24.17%
3-year revenue growth (CAGR)
9.13%
10-year revenue growth (CAGR)
12.70%
3-year earnings per share growth (CAGR)
-3.68%
10-year earnings per share growth (CAGR)
5.19%
3-year dividend per share growth (CAGR)
4.19%
10-year dividend per share growth (CAGR)
10.47%
What the Analysts think about BioGaia AB
Analyst ratings (Buy, Hold, Sell) for BioGaia AB stock.
Analyst projections of the future price of BioGaia AB stock.
Bulls say / Bears say
Third-quarter sales rose 23% and operating profit rose 54%, lifting the operating margin to 33%. Stronger profit growth than sales points to improved operating leverage. (BioGaia)
A renewed long-term exclusive agreement with Recordati gives BioGaia an established distribution platform in Spain and Portugal. The partnership offers a route to deepen access to two markets the company identifies as important. (BioGaia)
Some customers moved orders from the fourth quarter into the third, mainly in Pediatrics. That pull-forward could leave a weaker comparison or softer sales in the final quarter. (BioGaia)
International growth from the new Protectis Plus strain may take time: management said market-specific registration is needed, including US GRAS approval, and the rollout could extend over several years. This delays the product’s potential contribution and leaves launch timing uncertain. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
BioGaia AB Financial Performance
Revenues and expenses
BioGaia AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing BioGaia AB
Fund name | Fund size | Skr BIOG B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.06% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.